Greiner Bio-One North America, Inc. Announces New Product for the Stabilization of Urine Specimens

During this time period, the urine specimen can be stored or transported without refrigeration that would otherwise be required. The product is also manufactured with a safety cap that is leak proof yet easy to open allowing for a hygienic operating method, with no risk of the splashes or aerosols that can occur with a standard stopper. In addition, it is made from highly transparent PET plastic making it virtually unbreakable.

Reliable results can only be achieved in urine diagnostics if the correct preanalytical conditions are ensured. Urine collection, specimen transport, and further storage are critical factors for sample quality and can affect the results. Most important is the stabilization of urine, if the specimen cannot be analyzed within two hours (1). A particular problem is exponential bacterial growth, since certain bacteria divide every 20 minutes. This can lead to an overgrowth of pathogenic bacteria, making detection difficult. This problem can lead to inaccurate results particularly with longer transportation and processing times. It has been shown, that on average 15% of urine samples intended for urine culture are contaminated. (2)

The VACUETTE® Urine CCM Tube preserves specimen integrity and is therefore ideal for transport and processing of urine samples for microbiology culture.

Greiner Bio-One North America, Inc. is a privately held plastic manufacturing company located in Monroe, NC whose three divisions manufacture a variety of products for the medical and research fields. The manufactured products include plastic ware for the cultivation and analysis of cell and tissue cultures, microplates for high-throughput screening related to drug screening, products for blood and specimen collection, tests for the detection of bacteria and viruses, as well as, custom-made products. As an international manufacturer with global reach, Greiner Bio-One provides the manufacturing, distribution logistics and product application support to the world’s largest hospitals, pharmaceutical and biotechnology corporations.


For more information about Greiner Bio-One North America, Inc. please visit

1)             CLSI. Urinalysis; Approved Guideline – Third Edition. GP16-A3. Vol 29 No 4.

2)             Berkeris LG Jones BA Walsh MK and Wagar EA: Urin Culture Contamination: A College of American Pathologists Q-Probes Study of 127 Laboratories, Arch Pathol Lab Med. 2008 132(6):913-917